Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world

Felice Pasini, Carmen Barile, Donatella Caruso, Yasmina Modena, Anna Paola Fraccon, Laura Bertolaso, Daniela Menon, Francesca La Russa, Giorgio Crepaldi, Antonio Bononi, Roberto Spezzano, Roberto Padrini, Giuseppe Corona, Milena Gusella

Research output: Contribution to journalArticle

Abstract

Background Oral metronomic therapy (OMV) is particularly suitable for palliative care, and schedules adapted for unfit patients are advisable. This study investigated the effects of oral vinorelbine given every other day without interruption and its pharmacokinetic profile in patients with advanced lung cancer. Materials and Methods Ninety-two patients received OMV at doses of 20, 30 or 50 mg. Toxic events, clinical benefit and overall survival were analysed. Blood pharmacokinetics were evaluated in 82 patients. Results Median treatment duration and overall survival were 15 (range 1.3–144) and 32.3 weeks, respectively; fourty-eight (60%) patients experienced clinical benefit. Outcomes were unrelated to previous therapies, age, histology or comorbidities. Toxicity was associated with higher blood concentrations of the drug. Pharmacokinetics were stable for up to two years, and were not influenced by treatment line or age. Conclusions OMV produced non-negligible survival in patients and also showed stable long-term blood concentrations. The schedule of 20–30 mg every other day without interruption gave good tolerability and clinical benefit.

Original languageEnglish
Pages (from-to)927-932
Number of pages6
JournalInvestigational New Drugs
Volume36
Issue number5
DOIs
Publication statusPublished - Oct 1 2018

Keywords

  • Clinical benefit
  • NSCLC
  • Oral metronomic vinorelbine
  • Overall survival
  • Pharmacokinetics
  • Unfit patients

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world'. Together they form a unique fingerprint.

  • Cite this

    Pasini, F., Barile, C., Caruso, D., Modena, Y., Fraccon, A. P., Bertolaso, L., Menon, D., La Russa, F., Crepaldi, G., Bononi, A., Spezzano, R., Padrini, R., Corona, G., & Gusella, M. (2018). Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world. Investigational New Drugs, 36(5), 927-932. https://doi.org/10.1007/s10637-018-0631-8